# Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

> **NCT01527487** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 76 (actual)

## Conditions studied

- HER2 Negative Breast Cancer

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01527487
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-09
- **Final completion:** 2016-07
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2016-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527487, "Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT01527487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*